“Nationwide, the overuse of systemic anti-cancer therapy at the end of life remains a persistent problem,” Kerin Adelson, MD, corresponding author of the study, said in a statement.

Threats of a federal government shutdown have gone from being an October surprise to a recurring theme.

Premiums will more than double for millions of Affordable Care Act enrollees next year if Congress does not renew enhanced marketplace subsidies by year's end, according to a new analysis.

For patients with cancer grappling with nausea or vomiting due to their treatments may be able to find relief to this side effect through methods within their own reach.

A groundbreaking new study from the Alliance for Clinical Trials in Oncology aims to test whether digital tools and chatbot technology can help young adult cancer survivors get the genetic counseling they need to better understand future health risks to themselves and family members.

Easier access to telehealth services granted during the COVID-19 public health emergency allowed hundreds of thousands of Medicare patients in rural areas to obtain virtual care in the privacy of their homes, saving them the time, money, and the risk of getting an infection in traveling to a distant medical facility to receive it.

The fight over covid-era health insurance subsidies that could trigger a government shutdown highlights what even supporters of the Affordable Care Act fight admit is a flaw in the original law: It wasn’t generous enough to make plans affordable.

The Ways and Means Committee recently approved H.R. 842, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act – introduced by Representatives Jodey Arrington (TX-19) and Terri Sewell (AL-07) and named in honor of Representative Sewell’s late mother – to ensure timely access to innovative early-detection cancer screenings for Medicare beneficiaries.

U.S. pharmaceutical lobby group PhRMA said on Monday it would launch a new website in January to help patients buy prescription drugs directly from manufacturers, bypassing pharmacy benefit managers and other middlemen.